Brief: Cocrystal Pharma Enrollment Completed In Phase 2A Study With Oral Antiviral Candidate CC-42344
01/05/2024 13:31
May 1 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA INC: ENROLLMENT COMPLETED IN PHASE 2A
STUDY
WITH ORAL ANTIVIRAL CANDIDATE CC-42344 FOR PANDEMIC AND SEASONAL
INFLUENZA
* COCRYSTAL PHARMA: PLANS PHASE 1 STUDY IN AUSTRALIA WITH
INHALED
FORMULATION OF CC-42344 AS POTENTIAL INFLUENZA A TREATMENT &
POST-EXPOSURE PROPHYLAXIS
Source text for Eikon: ID:nGNX9hjfPv
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway